Abstract
FTY720 is a recently approved first line therapy for relapsing forms of multiple sclerosis. In this context, FTY720 is a pro-drug, with its anti-multiple sclerosis, immunosuppressive effects largely elicited following its phosphorylation by sphingosine kinase 2 and subsequent modulation of G protein-coupled sphingosine 1-phosphate (S1P) receptor 1 that induces lymphopenia by altering lymphocyte trafficking. A number of other biological effects of FTY720 have, however, been described, including considerable evidence that this drug also has anti-cancer properties. These other effects of FTY720 are independent of S1P receptors, and appear facilitated by modulation of a range of other recently described protein targets by nonphosphorylated FTY720. Here, we review the direct targets of FTY720 that contribute to its anti-cancer properties. We also discuss other recently described protein effectors that, in combination with S1P receptors, appear to contribute to its immunosuppressive effects.
Keywords: Apoptosis, cancer, FTY720, fingolimod, lymphopenia, lysophospholipid, sphingosine, sphingosine 1-phosphate, therapeutic drug, Gilenya™, myriocin, immunosuppressive activity, immuno-suppressants, toxicity, multiple sclerosis
Current Molecular Medicine
Title:Molecular Targets of FTY720 (Fingolimod)
Volume: 12 Issue: 10
Author(s): M.R. Pitman, J.M. Woodcock, A.F. Lopez and S.M. Pitson
Affiliation:
Keywords: Apoptosis, cancer, FTY720, fingolimod, lymphopenia, lysophospholipid, sphingosine, sphingosine 1-phosphate, therapeutic drug, Gilenya™, myriocin, immunosuppressive activity, immuno-suppressants, toxicity, multiple sclerosis
Abstract: FTY720 is a recently approved first line therapy for relapsing forms of multiple sclerosis. In this context, FTY720 is a pro-drug, with its anti-multiple sclerosis, immunosuppressive effects largely elicited following its phosphorylation by sphingosine kinase 2 and subsequent modulation of G protein-coupled sphingosine 1-phosphate (S1P) receptor 1 that induces lymphopenia by altering lymphocyte trafficking. A number of other biological effects of FTY720 have, however, been described, including considerable evidence that this drug also has anti-cancer properties. These other effects of FTY720 are independent of S1P receptors, and appear facilitated by modulation of a range of other recently described protein targets by nonphosphorylated FTY720. Here, we review the direct targets of FTY720 that contribute to its anti-cancer properties. We also discuss other recently described protein effectors that, in combination with S1P receptors, appear to contribute to its immunosuppressive effects.
Export Options
About this article
Cite this article as:
Pitman M.R., Woodcock J.M., Lopez A.F. and Pitson S.M., Molecular Targets of FTY720 (Fingolimod), Current Molecular Medicine 2012; 12 (10) . https://dx.doi.org/10.2174/156652412803833599
DOI https://dx.doi.org/10.2174/156652412803833599 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cerebrovascular Complications of Diabetes: SGLT-2 Inhibitors as a Promising Future Therapeutics
Current Drug Targets The Neurokinins: Peptidomimetic Ligand Design and Therapeutic Applications
Current Medicinal Chemistry The Dark Side of Stem Cells: Triggering Cancer Progression by Cell Fusion
Current Molecular Medicine Management of Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Current Immunology Reviews (Discontinued) Can we Consider Zoledronic Acid a New Antitumor Agent? Recent Evidence in Clinical Setting
Current Cancer Drug Targets The Management of Phosphodiesterase-5 (PDE5) Inhibitor Failure
Current Vascular Pharmacology Nitrogen-Containing Bisphosphonates and Cancer Immunotherapy
Current Pharmaceutical Design In Situ Gels Based Drug Delivery Systems
Current Drug Therapy The Role of B-Lymphocyte Stimulator in Neuroendocrine Tumors: Correlation with Tumor Differentiation, Disease status and the Presence of Metastases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Imatinib Mesylate for the Treatment of Solid Tumours: Recent Trials and Future Directions
Current Enzyme Inhibition Radiolabeled Glucose Derivatives for Tumor Imaging Using SPECT and PET
Current Medicinal Chemistry Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal Molecular Bases of Chemoresistance in Cholangiocarcinoma
Current Drug Targets Comparative Safety Assessment Study for Drospirenone Induced Gallbladder Diseases Using the Adverse Drug Reaction Database of USA, Europe, and Canada
Current Drug Safety Alternative Spliced Variants as Biomarkers of Colorectal Cancer
Current Drug Metabolism Fluorescence Detection of MMP-9. I. MMP-9 Selectively Cleaves Lys-Gly-Pro-Arg-Ser-Leu-Ser-Gly-Lys Peptide
Current Pharmaceutical Biotechnology Innovations and Opportunities to Improve Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer
Current Medicinal Chemistry New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer
Current Drug Targets Newer Avenues for the Treatment of Leptomeningeal Carcinomatosis
Central Nervous System Agents in Medicinal Chemistry Glycerophospholipid Synthesis as a Novel Drug Target Against Cancer
Current Molecular Pharmacology